<DOC>
	<DOCNO>NCT02319070</DOCNO>
	<brief_summary>This study prospective , single center , observational , 2-cohort study adult patient severe Hemophilia A . There randomization procedure patient treat per usual clinical practice . Patients follow 18 month enrolment .</brief_summary>
	<brief_title>2-cohort Study Adult Patients With Severe Hemophilia A Greece</brief_title>
	<detailed_description>The primary therapy hemophilia coagulation factor replacement , give either episodically demand ( OD ) treatment acute bleeds prophylactically prevent . The last year interest study comparative effectiveness OD vs. SP ( Secondary Prophylaxis ) treatment strategy create evidence base platform guide clinical decision make quantify economic aspect treatment alternative . In Greece relevant information lacking , thus imperative study patient different treatment strategy manage real-life setting Greece , include main factor associate increased health care utilization , clinical success patient well .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients diagnose severe Hemophilia A . Age â‰¥18 year old Patients able read write Patients receive Factor VIII substitute therapy , either ondemand secondary prophylaxis . Patients therapeutic strategy ( On Demand Secondary Prophylaxis ) least 6 month prior enrolment . Patients develop inhibitor factor VIII . Patients participate investigational program intervention outside routine clinical practice .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cost</keyword>
	<keyword>Clinical Outcomes</keyword>
	<keyword>Quality Life</keyword>
	<keyword>On Demand Treatment</keyword>
	<keyword>Secondary Prophylaxis</keyword>
</DOC>